Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

This study tests befotertinib — a targeted oral drug that blocks the EGFR mutation — as preventive treatment after surgery for patients with early-stage lung cancer (stage IA2–IB) who have an EGFR mutation and evidence of minimal residual disease detected in the blood. **You may be eligible if...** - You are aged 18–75 and had surgery for early-stage lung adenocarcinoma with clear margins - Your tumor tested positive for a sensitive EGFR mutation - A blood test after surgery showed residual cancer markers (MRD positive) - Your tumor is 1–4 cm and you have at least 2 high-risk features (e.g., blood vessel invasion, poor differentiation) **You may NOT be eligible if...** - You have received any treatment before surgery - You have had another cancer within the past 2 years - You have a history of interstitial lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.